According to MedCityNews, New York-based Aetion said Wednesday that it had raised the $19M extension to its Series B, completing the $82M financing. The investment came from three new shareholders - Johnson & Johnson Innovation - JJDC, EDBI and Greenspring Associates. Additional investors include NEA, Flare Capital, Lakestar, Sanofi, McKesson Ventures, Amgen Ventures, UCB and Blue Cross Blue Shield of New Jersey's Horizon Health Services.

Aetion (pronounced eh-tee-ahn) is a leading healthcare technology company that delivers the real-world analytics and evidence needed for value-based healthcare. With its patented rapid-cycle analytics™ technology, the platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care.